RTP-based Quill Medical, Inc. (www.quillmedical.com) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Quill Barbed Polydioxanone Suture, for wound closure of dermal tissue. The product is the first in a series of tissue repair devices that the company is developing. These products, based on Quill's patented technology, enable surgical sutures to “self-anchor” in tissue without the need of a suture knot.
This U.S. clearance follows last May's European marketing approval. Other products based on Quill Medical's patented suture technology have also recently been approved by the FDA for use as minimally-invasive devices for lifting skin in cosmetic surgery applications. The approval of the cosmetic surgery product was obtained in conjunction with its partner in the aesthetics field, Surgical Specialties Corp. of Reading, PA, and will be marketed under the name “Contour Thread,” according to company reports.
Quill Medical is a CED member.